Bintai Kinden Corp Bhd will collaborate with Institut Jantung Negara Sdn Bhd (IJN) in producing Covid-19 vaccine in Malaysia.
In a statement from Bintai Kinden, according to the Memorandum of Understanding (MOU) agreed with IJN in September 2020, it has entered into a cooperation agreement with the institution to establish a strategic partnership in the field of commercial development of Covid-19 vaccine.
According to the engineering company, the partnership is based on a collaboration between Bintai Healthcare Sdn Bhd (BHSB) subsidiary, Generex Biotechnology Corp (Generex) and NuGenerex Immuno-Oncology Inc to commercialize the Ii-Key-SARS-CoV-2 coronavirus vaccine (Covid-19). in Malaysia.
Under the agreement, Bintai Kinden is responsible for introducing the Covid-19 vaccine while IJN will conduct and lead the clinical trials required by the Ministry of Health.
According to Bintai Kinden's Chief Executive Officer (CEO), Azri Azerai, the collaboration with IJN will bring the company one step closer to introducing the new Covid-19 vaccine in Malaysia.
He further explained that upon receiving the Food and Drug Administration (FDA) approval, Generex will provide all documentation to BHSB to register the new vaccine with the National Pharmaceutical Regulatory Agency (NPRA) Malaysia.
In the meantime, Bintai Kinden will also hand over a check worth RM100,000 as a start-up grant to IJN through the establishment of the Covid 19 Research Grant, Bintai-IJN Healthcare to fund the necessary research programs.
